ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bioengineered Exosome-Loaded Immunomodulatory Bioadhesive Spray Reverses Liver Fibrosis and Metabolic Dysfunction That Triggers Beneficial Gut-Liver Crosstalk in Chronic Fatty Liver Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a progressive liver disorder with complex pathogenesis and no approved treatments beyond lifestyle changes. Here, we report a sprayable and biodegradable bioadhesive hydrogel loaded with exosomes derived from human mesenchymal stromal cells that provides sustained therapy localized to the liver. In a rat model of chronic MAFLD, a single application of the spray markedly improved liver pathology and systemic metabolic indices over the effects of lifestyle interventions. Specifically, collagen deposition, liver-enzyme levels, insulin resistance, and chronic inflammation were all attenuated. Furthermore, the spray led to an increase in markers of gut-barrier integrity and gut bacterial diversity and modulated key pathways of lipid metabolism, inflammation, and fibrosis, as we show via multi-omics profiling of liver tissue. Our findings strongly suggest that exosomes delivered to the liver via a sprayable anti-inflammatory hydrogel can address the multifactorial pathology of MAFLD, yielding improvements in liver histology and function, and inducing systemic metabolic homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.